Philip L. McCarthy MD

Philip L. McCarthy, MD, is a Professor of Oncology and Internal Medicine, Director Emeritus of the Transplant and Cellular Therapy (TCT) Program, and a member of the Department of Medicine at Roswell Park Comprehensive Cancer Center/SUNY at Buffalo.

Dr. McCarthy’s research interests are devoted to developing novel intensive and reduced intensity allogeneic and autologous hematopoietic stem cell transplant (HSCT) approaches for the treatment of hematologic disorders, leading to improved patient outcomes and decreased toxicity. He has over 25 years of experience treating patients with hematologic disorders, directing clinical and translational studies with a particular interest in multiple myeloma (MM).

Dr. McCarthy has served as chair, or co-chair, of several clinical trials, including CALGB 100104, a phase III clinical trial evaluating lenalidomide maintenance after autologous HSCT for MM. This study demonstrated an improved progression-free and overall survival for MM patients receiving lenalidomide maintenance therapy after autologous HSCT. Dr. McCarthy facilitates the development of translational research projects that will lead to advances in the utilization of cellular therapy including immune effector cell treatment and allogeneic (allo) HCT as well as developing strategies for the early, successful treatment of hematologic malignancies.